

Laura Ciaffi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9493245/publications.pdf>

Version: 2024-02-01

11
papers

211
citations

1683354

5
h-index

1372195

10
g-index

11
all docs

11
docs citations

11
times ranked

428
citing authors

#	ARTICLE	IF	CITATIONS
1	Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12) Tj ETQq1,1 0.784314 rgBT 0 e384-e392.	2.1	63
2	Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa. <i>Aids</i> , 2015, 29, 1473-1481.	1.0	39
3	SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon. <i>Nature Communications</i> , 2021, 12, 5851.	5.8	38
4	Short Communication: High Viral Load and Multidrug Resistance Due to Late Switch to Second-Line Regimens Could Be a Major Obstacle to Reach the 90-90-90 UNAIDS Objectives in Sub-Saharan Africa. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 1159-1162.	0.5	28
5	Chronic kidney disease and HIV in the era of antiretroviral treatment: findings from a 10-year cohort study in a west African setting. <i>BMC Nephrology</i> , 2019, 20, 155.	0.8	22
6	The Follow-Up and Well-Being of Geriatric Outpatients During COVID-19 Pandemic in Cameroon: Insights From the Yaounde Central Hospital. <i>Gerontology and Geriatric Medicine</i> , 2020, 6, 233372142095924.	0.8	5
7	APOL1 Renal Risk Variants and Kidney Function in HIV-1-Infected People From Sub-Saharan Africa. <i>Kidney International Reports</i> , 2022, 7, 483-493.	0.4	5
8	Short Communication: Nucleoside Reverse Transcriptase Inhibitors with Reduced Predicted Activity Do Not Impair Second-Line Therapy with Lopinavir/Ritonavir or Darunavir/Ritonavir. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 477-480.	0.5	4
9	Deep sequencing analysis of M184V/I mutation at the switch and at the time of virological failure of boosted protease inhibitor plus lamivudine or boosted protease inhibitor maintenance strategy (substudy of the ANRS-MOBIDIP trial). <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1286-1293.	1.3	4
10	Field evaluation of an open and polyvalent universal HIV-1/SIVcpz/SIVgor quantitative RT-PCR assay for HIV-1 viral load monitoring in comparison to Abbott RealTime HIV-1 in Cameroon. <i>Journal of Virological Methods</i> , 2016, 237, 121-126.	1.0	3
11	Implementation and evaluation of a therapeutic patient education programme during a clinical trial in Yaounde, Cameroon - Trial ANRS-12286/MOBIDIP. <i>Patient Education and Counseling</i> , 2018, 101, 1262-1269.	1.0	0